u/lulmagician · 243d agono track record yet
“stacking position for a few days, currently balls deep into this”
Did a thing - IBRX
IBRX is executing on ANKTIVA commercialization with $113M in 2025 revenue (700% YoY growth) and recent NSCLC approval in Saudi Arabia de-risks the solid tumor platform. Upcoming BCG-naïve trial completion (Q2 2026) could expand TAM by moving the drug to earlier treatment lines, driving further upside.
At post $6.21Now $8.14+31.1% since postedas of Sep 15, 4:30 PM ET